相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytokines in the Treatment of Cancer
Kevin C. Conlon et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
Jeffrey Yang et al.
MEDICINAL RESEARCH REVIEWS (2019)
Oncolytic viruses: overcoming translational challenges
Jordi Martinez-Quintanilla et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Cytosolic DNA-sensing immune response and viral infection
Takayuki Abe et al.
MICROBIOLOGY AND IMMUNOLOGY (2019)
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity
Hiroshi Yano et al.
IMMUNOLOGY (2019)
Immune System Stimulation by Oncolytic Rodent Protoparvoviruses
Assia Angelova et al.
VIRUSES-BASEL (2019)
Macrophage Polarization in the Development and Progression of Ovarian Cancers: An Overview
Huiyan Cheng et al.
FRONTIERS IN ONCOLOGY (2019)
H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future
Clemens Bretscher et al.
VIRUSES-BASEL (2019)
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Francesca Maria Consonni et al.
FRONTIERS IN IMMUNOLOGY (2019)
Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
Felix L. Fennemann et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Tianyi Liu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Treg-mediated acquired resistance to immune checkpoint inhibitors
Reem Saleh et al.
CANCER LETTERS (2019)
Classification of tumor microenvironment immune types based on immune response-associated gene expression
Ryota Kondou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Tumor microenvironment: Interactions and therapy
Masoud Najafi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Fernando Souza-Fonseca-Guimaraes et al.
TRENDS IN IMMUNOLOGY (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
RIG-I and Other RNA Sensors in Antiviral Immunity
Kwan T. Chow et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
Oncogene-induced senescence and tumour control in complex biological systems
Lorenzo Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2018)
Anti-cancer therapy with TNFα and IFNγ:A comprehensive review
Jing Shen et al.
CELL PROLIFERATION (2018)
Armed oncolytic viruses: A kick-start for anti-tumor immunity
J. F. de Graaf et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Stephen J. Bagley et al.
NEURO-ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy
Marie-Claude Bourgeois-Daigneault et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells
Matthew A. Lakins et al.
NATURE COMMUNICATIONS (2018)
Talimogene laherparepvec: First in class oncolytic virotherapy
Robert M. Conry et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Current status and future directions of cancer immunotherapy
Hongming Zhang et al.
JOURNAL OF CANCER (2018)
Viruses Seen by Our Cells: The Role of Viral RNA Sensors
Elias A. Said et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Immunotherapies: Exploiting the Immune System for Cancer Treatment
Jeffrey Koury et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Aurelie Durgeau et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Carole Achard et al.
EBIOMEDICINE (2018)
Toxicity of immune checkpoints inhibitors
M. Delaunay et al.
REVUE DES MALADIES RESPIRATOIRES (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
Ibrahim Ragab Eissa et al.
CANCERS (2018)
Harnessing the immune system in glioblastoma
Nicholas F. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
Joshua D. Freedman et al.
CANCER RESEARCH (2018)
Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches
Li Teng Khoo et al.
EMBO REPORTS (2018)
ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE
Karsten Geletneky et al.
NEURO-ONCOLOGY (2018)
Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity
Aleksey Molodtsov et al.
FRONTIERS IN IMMUNOLOGY (2018)
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Sonia Guedan et al.
FRONTIERS IN IMMUNOLOGY (2018)
The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity
Valentina Poltavets et al.
FRONTIERS IN ONCOLOGY (2018)
Deciphering the Role of Regulatory CD4 T Cells in Oral and Oropharyngeal Cancer: A Systematic Review
Caoimhin O' Higgins et al.
FRONTIERS IN ONCOLOGY (2018)
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Christopher J. LaRocca et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Development and applications of oncolytic Maraba virus vaccines
Jonathan G. Pol et al.
ONCOLYTIC VIROTHERAPY (2018)
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
E. Ilett et al.
GENE THERAPY (2017)
ATIM-29. FIRST CLINICAL OBSERVATION OF IMPROVED ANTI-TUMOR EFFECTS OF VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH PD-1 CHECKPOINT BLOCKADE AND BEVACICUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Karsten Geletneky et al.
NEURO-ONCOLOGY (2017)
Virotherapy Research in Germany: From Engineering to Translation
Guy Ungerechts et al.
HUMAN GENE THERAPY (2017)
Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector-Host Interactions for Therapy
Claudia Hagedorn et al.
HUMAN GENE THERAPY (2017)
Immune recognition of irradiated cancer cells
Erik Wennerberg et al.
IMMUNOLOGICAL REVIEWS (2017)
The SAT Protein of Porcine Parvovirus Accelerates Viral Spreading through Induction of Irreversible Endoplasmic Reticulum Stress
Istvan Meszaros et al.
JOURNAL OF VIROLOGY (2017)
Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage
Suhong Qian et al.
JOURNAL OF VIROLOGY (2017)
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Nicholas M. Durham et al.
MOLECULAR THERAPY (2017)
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Karsten Geletneky et al.
MOLECULAR THERAPY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs
Michael C. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
Assia L. Angelova et al.
VIRUSES-BASEL (2017)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Adipocytes and Macrophages interplay in the Orchestration of Tumor Microenvironment: New implications in Cancer Progression
Luis Henrique Correa et al.
FRONTIERS IN IMMUNOLOGY (2017)
Type I Interferons and Natural Killer Cell Regulation in Cancer
Lena Mueller et al.
FRONTIERS IN IMMUNOLOGY (2017)
Prospects for combined use of oncolytic viruses and CAR T-cells
Adam Ajina et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
Jacek Hajda et al.
BMC CANCER (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Microenvironmental regulation of tumour angiogenesis
Michele de Palma et al.
NATURE REVIEWS CANCER (2017)
B cell regulation in cancer and anti-Xtumor immunity
Anushruti Sarvaria et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Renal complications of immune checkpoint blockade
Naoka Murakami et al.
CURRENT PROBLEMS IN CANCER (2017)
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Mee Y. Bartee et al.
CANCER RESEARCH (2017)
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Carlos Alberto Fajardo et al.
CANCER RESEARCH (2017)
The Microenvironmental Landscape of Brain Tumors
Daniela F. Quail et al.
CANCER CELL (2017)
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies
Amelia Sadie Aitken et al.
BIOMEDICINES (2017)
A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet
Gabriele D'Errico et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Activation of apoptosis signalling pathways by reactive oxygen species
Maureen Redza-Dutordoir et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Immune Checkpoint Therapy and the Search for Predictive Biomarkers
Padmanee Sharma
CANCER JOURNAL (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Immune suppressive mechanisms in the tumor microenvironment
David H. Munn et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
The host STING pathway at the interface of cancer and immunity
Leticia Corrales et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
Antonio Marchini et al.
VIRUSES-BASEL (2016)
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter et al.
ONCOIMMUNOLOGY (2016)
Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus
Ferdaous Allagui et al.
CURRENT GENE THERAPY (2016)
YVEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
Rozanne Arulanandam et al.
CANCER CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Regulatory B Cells: Origin, Phenotype, and Function
Elizabeth C. Rosser et al.
IMMUNITY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Cancer-fighting viruses win approval
Heidi Ledford
NATURE (2015)
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity
Carolina S. Ilkow et al.
NATURE MEDICINE (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
ATNT-07FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB
Karsten Geletneky et al.
NEURO-ONCOLOGY (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Oncolytic parvoviruses: from basic virology to clinical applications
Antonio Marchini et al.
VIROLOGY JOURNAL (2015)
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
Youra Kim et al.
VIRUSES-BASEL (2015)
Double-faceted mechanism of parvoviral oncosuppression
Karsten Geletneky et al.
CURRENT OPINION IN VIROLOGY (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Tumor selectivity of oncolytic parvoviruses: from in vitro and animal models to cancer patients
Assia L. Angelova et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Interferon-α Acts on the S/G2/M Phases to Induce Apoptosis in the G1 Phase of an IFNAR2-expressing Hepatocellular Carcinoma Cell Line
Sakae Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer
Assia L. Angelova et al.
JOURNAL OF VIROLOGY (2014)
Autonomous Parvoviruses neither Stimulate nor Are Inhibited by the Type I Interferon Response in Human Normal or Cancer Cells
Justin C. Paglino et al.
JOURNAL OF VIROLOGY (2014)
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Christine E. Engeland et al.
MOLECULAR THERAPY (2014)
Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies
Samuel T. Workenhe et al.
MOLECULAR THERAPY (2014)
Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus
Elizabeth Ilett et al.
MOLECULAR THERAPY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
Stephen J. Russell et al.
MAYO CLINIC PROCEEDINGS (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
Pia Kvistborg et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Oncolytic Viruses and Their Application to Cancer Immunotherapy
E. Antonio Chiocca et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Immune-suppressive properties of the tumor microenvironment
Juergen C. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Caroline J. Breitbach et al.
CANCER RESEARCH (2013)
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas
Junwei Li et al.
EMBO MOLECULAR MEDICINE (2013)
Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1
Maike Sieben et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
RAGE and TLRs: Relatives, friends or neighbours?
Zaridatul Aini Ibrahim et al.
MOLECULAR IMMUNOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
TLR-9 Contributes to the Antiviral Innate Immune Sensing of Rodent Parvoviruses MVMp and H-1PV by Normal Human Immune Cells
Zahari Raykov et al.
PLOS ONE (2013)
Parvovirus evades interferon-dependent viral control in primary mouse embryonic fibroblasts
Lisa M. Mattei et al.
VIROLOGY (2013)
Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis
Muriel Lavie et al.
VIROLOGY (2013)
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells
Bernd Heinrich et al.
ONCOTARGETS AND THERAPY (2013)
Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
Karsten Geletneky et al.
BMC CANCER (2012)
A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity
James R. Tysome et al.
CLINICAL CANCER RESEARCH (2012)
Molecular Pathways: Rodent Parvoviruses-Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment
Juerg P. F. Nueesch et al.
CLINICAL CANCER RESEARCH (2012)
Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Sonia Tusell Wennier et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
J. D. Dias et al.
GENE THERAPY (2012)
The tumor microenvironment at a glance
Frances R. Balkwill et al.
JOURNAL OF CELL SCIENCE (2012)
Generation of an Adenovirus-Parvovirus Chimera with Enhanced Oncolytic Potential
Nazim El-Andaloussi et al.
JOURNAL OF VIROLOGY (2012)
Activation of a Helper and Not Regulatory Human CD4+T Cell Response by Oncolytic H-1 Parvovirus
Olivier Morales et al.
PLOS ONE (2012)
Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
Robert A. Adair et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Efficient Recombinant Parvovirus Production with the Help of Adenovirus-derived Systems
Nazim El-Andaloussi et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1
Markus Moehler et al.
BMC CANCER (2011)
Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer
Svitlana P. Grekova et al.
CANCER BIOLOGY & THERAPY (2011)
Novel adenovirus-based helper system to support production of recombinant parvovirus
N. El-Andaloussi et al.
CANCER GENE THERAPY (2011)
Enhancement of NK cell antitumor responses using an oncolytic parvovirus
Rauf Bhat et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells
Mena Mansour et al.
JOURNAL OF VIROLOGY (2011)
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach et al.
NATURE (2011)
Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent
Svitlana Grekova et al.
CANCER BIOLOGY & THERAPY (2010)
Oncolytic parvoviruses as cancer therapeutics
Jean Rommelaere et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Activation of an Antiviral Response in Normal but Not Transformed Mouse Cells: a New Determinant of Minute Virus of Mice Oncotropism
Svitlana Grekova et al.
JOURNAL OF VIROLOGY (2010)
Through Its Nonstructural Protein NS1, Parvovirus H-1 Induces Apoptosis via Accumulation of Reactive Oxygen Species
Georgi Hristov et al.
JOURNAL OF VIROLOGY (2010)
Intelligent Design: Combination Therapy With Oncolytic Viruses
Kathryn Ottolino-Perry et al.
MOLECULAR THERAPY (2010)
Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models
Karsten Geletneky et al.
NEURO-ONCOLOGY (2010)
Metabolism and proliferation share common regulatory pathways in cancer cells
V. Fritz et al.
ONCOGENE (2010)
PEGylated Adenoviruses: From Mice to Monkeys
Piyanuch Wonganan et al.
VIRUSES-BASEL (2010)
Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV
Assia L. Angelova et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Michael R. Elliott et al.
NATURE (2009)
Type I interferon as a stimulus for cross-priming
Agnes Le Bon et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2008)
Interferon-inducible antiviral effectors
Anthony J. Sadler et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells
Matteo Di Piazza et al.
JOURNAL OF VIROLOGY (2007)
Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte
SJ Gardai et al.
CELL (2005)
Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells
MH Moehler et al.
HUMAN GENE THERAPY (2005)
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma
F Benencia et al.
HUMAN GENE THERAPY (2005)
Cutting edge: Type IIFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation
JM Curtsinger et al.
JOURNAL OF IMMUNOLOGY (2005)
Multimutated herpes simplex virus G207 is a potent inhibitor of angiogenesis
J Cinatl et al.
NEOPLASIA (2004)
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
S Kostense et al.
AIDS (2004)
Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells
M Moehler et al.
CANCER GENE THERAPY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Coordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection
KB Nguyen et al.
JOURNAL OF IMMUNOLOGY (2002)
Type I interferons produced by dendritic cells promote their phenotypic and functional activation
M Montoya et al.
BLOOD (2002)
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
DF Stojdl et al.
NATURE MEDICINE (2000)
分享论文
